Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia
Authors
Keywords
-
Journal
BLOOD
Volume 139, Issue 11, Pages 1766-1770
Publisher
American Society of Hematology
Online
2022-03-18
DOI
10.1182/blood.2021014401
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
- (2021) Edmond Chiche et al. Blood Advances
- Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
- (2021) Kishan K. Patel et al. Blood Advances
- CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
- (2021) Jeffrey E Lancet et al. Lancet Haematology
- Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia
- (2021) Jan Philipp Bewersdorf et al. Blood Advances
- Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia
- (2020) Kathleen F. Villa et al. JOURNAL OF MEDICAL ECONOMICS
- CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
- (2020) Fabio Guolo et al. Blood Cancer Journal
- Health state utilities associated with treatment options for acute myeloid leukemia (AML)
- (2019) Louis S. Matza et al. JOURNAL OF MEDICAL ECONOMICS
- Medicare Cost at End of Life
- (2019) Ian Duncan et al. American Journal of Hospice & Palliative Medicine
- CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (
- (2019) Dasom Lee et al. BLOOD
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States
- (2018) Jill A. Bell et al. LEUKEMIA RESEARCH
- Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations
- (2018) Eytan M. Stein et al. JOURNAL OF MEDICAL ECONOMICS
- Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse
- (2016) William Irish et al. CURRENT MEDICAL RESEARCH AND OPINION
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Economic burden associated with acute myeloid leukemia treatment
- (2015) Amer M Zeidan et al. Expert Review of Hematology
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started